The details of the presentation are as follows:
Session: Immunotherapy (Immune checkpoints, Vaccination, Oncolytic viruses, Cytokines)
Poster Board Number: 132
Abstract Number in Proceedings Book: 138
Poster Viewing Session:
Location: Exhibition Hall
Title: "Preclinical activity and safety of MGD006, a CD123 x CD3 Bispecific DART® molecule for the treatment of hematological malignancies"
MGD006 is a humanized DART molecule that recognizes both CD123 and CD3. The molecule was designed to redirect T cells via their CD3 component to kill CD123-expressing cells, as shown pre-clinically. CD123, the Interleukin-3 receptor alpha chain, has been reported to be overexpressed on malignant cells in a wide range of hematological malignancies including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). AML and MDS are thought to arise from a small population of leukemic stem cells (LSCs) that generally resist conventional chemotherapeutic agents. LSCs are characterized by high levels of CD123 expression that is low or absent in the corresponding normal hematopoietic stem cell population. This product candidate is currently being tested in a Phase 1 clinical study in patients with relapsed or refractory AML.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risk factors described in the Company's filings with the
Jim Karrels, Vice President, CFO MacroGenics, Inc.1-301-251-5172, email@example.com Karen Sharma, Vice President MacDougall Biomedical Communications1-781-235-3060, firstname.lastname@example.org
News Provided by Acquire Media